X4 Pharmaceuticals to Present and Participate in the Canaccord Genuity’s 40th Annual Growth Conference

A live webcast of the presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com .

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Monday, August 10, 2020
Information
Tags: 
Chemokine receptors, Branches of biology, CXCR4, CXC chemokine receptors, HIV, Chemokine
Geotags: 
Cambridge, Ma, Us
Organisation: 
X4 PHARMACEUTICALS
Summary
Key Points: 
  • A live webcast of the presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com .
  • After the live webcasts, the events will remain archived on the X4 Pharmaceuticals website for approximately 90 days.
  • The Companys lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.
  • X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters inCambridge, Massachusettsand at its research facility inVienna,Austria, and is discovering and developing additional product candidates.


CAMBRIDGE, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct one-on-one meetings during the Virtual Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12th, 2020 at 2:30 pm Eastern Time.

A live webcast of the presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com. After the live webcasts, the events will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The Company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.  X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia.  X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Cambridge, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 
Candice Ellis, 857-341-1043 
Director, Corporate Communications & Investor Relations 
[email protected]

Primary Logo
Copyright: 
2020 GlobeNewswire, Inc.. All Rights Reserved.